Safety Issue
(click here to sort) |
Date
(click here to sort) | Safety Information |
|---|
|
Zolpidem and Proposed Lower Doses Due to Impaired Mental Alertness
|
01/16/2013
|
National PBM Communication
|
|
Ondansetron 32mg Single IV Dose Market Withdrawal Due to Cardiac Risks
|
12/05/2012
|
National PBM Bulletin
|
|
Dabigatran (Pradaxa®) and Packaging Error - Recall Due to Possible Compromise in Product Quality
|
11/09/2012
|
National PBM Communication
|
|
Ameridose Recall of All Unexpired Product Line
|
11/01/2012
|
National PBM Communication
|
|
ADDENDUM: Fungal Meningitis Outbreak and Additional Patient Notification
|
10/18/2012
|
National PBM Communication
|
|
Compounded Epidural Steroid Injections and Meningitis Outbreak
|
10/05/2012
|
National PBM Communication
|
| Citalopram (Celexa®) and Dose-Dependent QT Interval Prolongation: UPDATED RECOMMENDATIONS
|
04/17/2012
|
National PBM Bulletin
|
| Lo/Ovral-28 and Norgestrel/Ethinyl Estradiol Tablets - Recall for Inexact Tablet Counts or Out of Sequence Tablets
|
02/03/2012
|
National PBM Communication
|
| Aliskiren: Adverse Drug Events When Concomitantly Used with ACE Inhibitors or ARBs in Patients with Type II DM
|
01/13/2012
|
National PBM Bulletin
|
| Dronedarone and Cardiovascular Events in Permanent Atrial Fibrillation
|
01/10/2012
|
National PBM Communication
|
| Lexiscan® (Regadenoson) Update: New Safety Labeling Changes Approved By FDA |
11/15/2011 |
National PBM Communication |
| Target Dose of Angiotensin II Receptor Antagonists in Patients with Heart Failure |
10/31/2011 |
National PBM Communication |
| Citalopram Hydrobromide (Celexa®) and Dose-Dependent QT Interval Prolongation: UPDATE |
09/29/2011 |
National PBM Bulletin |
| Oral Contraceptives and Packaging Error Recall |
09/21/2011 |
National PBM Communication |
| Citalopram Hydrobromide (Celexa®) and Dose-Dependent QT Interval Prolongation |
08/31/2011 |
National PBM Bulletin |
| Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease (CKD) and New Dosing Recommendations |
08/09/2011 |
National PBM Communication |
| Dronedarone (Multaq®) and Risk of Death and Serious CV Events in Patients with Permanent AF |
07/28/2011 |
National PBM Communication |
| Colistimethate for Injection and Dosing Confusion |
07/08/2011 |
National PBM Bulletin |
| Recall of Butalbital, APAP, and Caffeine Tablets and Hydrocodone Bitartrate and APAP Tablets – Mislabeling |
06/30/2011 |
National PBM Communication |
| Churchill Medical Skin-Prep Wipes Recall Due to Bacterial Contamination |
06/17/2011 |
National PBM Communication |
| SimplyThick Thickening Gel Products Recall and Possible Presence of Bacteria |
06/10/2011 |
National PBM Communication |
| Simvastatin: Updated Restrictions, Contraindications and Dose Limitations |
06/09/2011 |
National PBM Bulletin |
| ADDENDUM: Warfarin and High Potency_EXPANDED Recall |
06/02/2011 |
National PBM Communication |
| ADDENDUM: Smith & Nephew Various Adhesive Remover Wipes and Potential Contamination_RECALL |
05/31/2011 |
National PBM Communication |
| Nitroglycerin Tablets and Packaging Error Recall |
05/25/2011 |
National PBM Communication |
| Smith & Nephew Various Adhesive Remover Wipes and Potential Contamination RECALL |
05/20/2011 |
National PBM Communication |
| Marcaine Incorrect Labeling and Potential Look-Alike Confusion |
05/13/2011 |
National PBM Bulletin |
| Warfarin and High Potency Recall |
05/12/2011 |
National PBM Communication |
| Citalopram and Finasteride Recall Due to Mislabeling |
03/31/2011 |
National PBM Communication |
| Povidine® Iodine Prep Pads and Potential Microbial Contamination Recall |
03/29/2011 |
National PBM Communication |
| Dexamethasone Sodium Phosphate Inj USP 4mg/ml and Particulate Formation Recall |
03/23/2011 |
National PBM Communication |
| PPIs: Long-Term Use and Risk of Hypomagnesemia |
03/11/2011 |
National PBM Communication |
| Dicyclomine and Doxycycline LASA Confusion |
03/10/2011 |
National PBM Bulletin |
| Maternal and Newborn Risks with Certain Medications Used During Pregnancy |
03/09/2011 |
National PBM Communication |
| Albuterol Sulfate Inhalation Solution Recall- Packaging Error |
02/11/2011 |
National PBM Communication |
| Dronedaraone and Liver Injury |
01/27/2011 |
National PBM Communication |
| Triad Group Recall – Sterile Lubricating Jelly and Alcohol Swabs |
01/20/2011 |
National PBM Communication |
| Abbott Glucose Test Strips Recall |
12/28/2010 |
National PBM Communication |
| Propoxyphene and Cardiac Toxicity |
11/19/2010 |
National PBM Bulletin |
| Dronedaraone and Adverse Events Reported in ISMP |
11/15/2010 |
National PBM Communication |
| Epoetin Alfa (Epogen and Procrit) Voluntary Recall |
09/28/2010 |
National PBM Communication |
| Regadenoson (Lexiscan) and Updated Labeling |
09/22/2010 |
National PBM Communication |
| New Considerations for the Safe and Effective Use of Colchicine |
07/15/2010 |
National PBM Bulletin |
| Heparin and Potency Variation: UPDATE |
04/07/2010 |
National PBM Communication |
| Clopidogrel and Boxed Warning Regarding Poor Metabolizers |
03/25/2010 |
National PBM Bulletin |
| LABA Safety in Asthmatic Patients |
03/09/2010 |
National PBM Communication |
| Clopidogrel and Omeprazole Drug Interaction |
02/12/2010 |
National PBM Bulletin |
| Natalizumab and the Risk for Developing PML and IRIS |
02/09/2010 |
National PBM Bulletin |
| Sirolimus Monitoring |
01/22/2010 |
National PBM Bulletin |
| Safety of High Dose Statin-Fibrate Combinations |
11/10/2009 |
National PBM Bulletin |
| Influenza Vaccine Adverse Event Reporting |
10/19/2009 |
National PBM Bulletin |
| Heparin and Potency Variation |
10/02/2009 |
National PBM Communication |
| Sitagliptin and Acute Pancreatitis |
09/29/2009 |
National PBM Communication |
| Vitamin D: High Dose Use and Safety |
09/15/2009 |
National PBM Bulletin |
| Fentanyl Transdermal System Recall Due to Leaking Contents |
08/20/2009 |
National PBM Communication |
| Dextroamphetamine/Amphetamine 20mg Tablet recall Due to Weight Variability |
08/20/2009 |
National PBM Communication |
| Risk of Severe Hypoglycemia with Glyburide Use in Elderly Patients with Renal Insufficiency |
07/29/2009 |
National PBM Bulletin |
| Propofol and Urgent Drug Recall by Teva Due to Contaminated Lots |
07/14/2009 |
National PBM Communication |
| Medtronic and Quick-Set Infusion Sets Recall |
07/13/2009 |
National PBM Communication |
| Varenicline and Bupropion and Neuropsychiatric Adverse Events |
07/02/2009 |
National PBM Communication |
| Oxybutynin and Oxycodone and LASA Confusion |
07/02/2009 |
National PBM Bulletin |
| Citalopram and Tablet Size Variance Recall |
06/30/2009 |
National PBM Communication |
| Tacrine and Tacrolimus LASA Confusion |
06/25/2009 |
National PBM Bulletin |
| Leukotriene Inhibitors and Neuropsychiatric Adverse Events |
06/15/2009 |
National PBM Communication |
| TNF-a Blockers, including Simponi [golimumab], and Risk of
Fungal Infections |
05/27/2009 |
FDA MedWatch Safety Alert |
| Macrodantin and Macrobid LASA Confusion |
05/06/2009 |
National PBM Bulletin |
| Regadenoson (Lexiscan) and Updated Labelling |
05/05/2009 |
National PBM Communication |
| Clevidipine and Propofol Potential Look-Alike Confusion |
04/30/2009 |
National PBM Communication |
| Ceftriaxone (Rocephin) and Calcium Interaction |
04/29/2009 |
National PBM Communication |
| Digoxin and Tablet Size Variability Recall |
04/02/2009 |
National PBM Communication |
| Infed (Iron Dextran) and Precipitate Formation Recall | 04/02/2009 |
National PBM Communication |
| Propafenone HCL 225mg (Watson) and Variability in Active Ingredient Recall | 03/30/2009 |
FDA Recall – Firm Press Release |
| Transdermal Patches Containing Metal and Risk of Burns | 03/05/2009 |
FDA Public Health Advisory |
| Rapitiva (Efalizumab) and PML | 03/03/2009 |
National PBM Communication |
| Metoclopramide and Risk of Tardive Dyskinesia | 02/26/2009 |
FDA News |
| Zonisamide (marketed as Zonegran, and generics) and Possible Metabolic Acidosis | 02/23/2009 |
FDA Information for Healthcare Professionals |
| Clopidogrel and Alteration of Effectiveness Due to CYP219 Inhibition | 01/29/2009 |
National PBM Communication |
| Duragesic Patch (50mcg/hr) and Cut in Drug Reservoir Recall | 12/31/2008 |
Johnson and Johnson News |
| Visicol and Osmoprep and Acute Phosphate Nephropathy |
12/19/2008 |
National PBM Communication |
| Methadone QTc Prolongation and Torsades de Pointes | 12/17/2008 |
National PBM Communication |
| LIFESCAN OneTouch SureStep Test Strips and Inaccurate Readings – RECALL | 12/04/2008 | National PBM Communication |
| Phenytoin and Fosphenytoin and Serious Skin Reactions | 12/03/2008 | National PBM Communication |
| Erlotinib (Tarceva) and Hepatic Impairment | 12/01/2008 | National PBM Communication |
| ETHEX Recall | 11/14/2008 | National PBM Communication |
| ETHEX Propafenone Recall Patient Letter | 11/12/2008 | National PBM Communication |
| ETHEX Recall | 11/12/2008 | National PBM Communication |
| Concentrated Opioid Solutions and Concentration Confusion | 11/12/2008 | National PBM Bulletin |
| Natalizumab and PML | 10/31/2008 | National PBM Communication |
| Varenicline and Increase in Reports of Serious Adverse Events | 10/28/2008 | National PBM Communication |
| Iron Dextran and the Adverse Drug Events Associated with the High Molecular Weight Formulation | 10/21/2008 | National PBM Bulletin |
| Calcium and Vitamin D and Change in Formulation | 10/06/2008 | National PBM Bulletin |
| Look-Alike Error with Acetic Acid and Sterile Water Irrigation | 10/02/2008 | National PBM Bulletin |
| Rituximab and PML | 9/19/2008 | National PBM Communication |
| TNF Inhibitors and the Risk for Invasive Fungal Infections | 09/05/2008 | National PBM Bulletin |
| EPOGEN® and Amgen Announcing Nationwide Voluntary Recall | 08/28/2008 | Patient Letter |
| EPOGEN® and Amgen Announcing Nationwide Voluntary Recall | 08/28/2008 | National PBM Communication |
| Natalizumab and PML | 08/27/2008 | National PBM Communication |
| Ezetimibe/Simvastatin (Vytorin®), Simvastatin, and Ezetimibe (Zetia®) and Risk for Cancer | 08/26/2008 | National PBM Communication |
| Naltrexone Injection Site Reactions | 08/20/2008 | National PBM Alert |
| Exenatide (Byetta) and Hemorrhagic and Necrotizing Pancreatitis | 08/19/2008 | National PBM Response |
| Naltrexone Injection Site Reactions | 8/20/2008 | National PBM Alert |
| Simvastatin and Amiodarone Drug-Drug Interaction | 8/18/2008 | National PBM Response |
| Mitoxantrone and Recommendations for Increased Monitoring | 8/18/2008 | National PBM Response |
| PROCRIT® (EPOETIN ALFA) LOT NUMBER P114942A and Nationwide Voluntary Recall of Ortho Biotech | 8/8/2008 | National PBM Response |
| PROCRIT® (EPOETIN ALFA) LOT NUMBER P114942A and Nationwide Voluntary Recall of Ortho Biotech – Patient Letter | 8/8/2008 | Patient Letter |
| Erythropoiesis Stimulating Agents (ESAs ): FDA Labeling Changes for Cancer Patients Receiving Myelosuppressive Chemotherapy | 8/8/2008 | National PBM Update Alert |
| Topical Thrombin and Safety Issues if Used Intravascularly | 8/7/2008 | National PBM Alert |
| Bevacizumab Plus Sunitinib and Potential for Developing Microangiopathic Hemolytic Anemia | 7/31/2008 | National PBM Alert |
| Micro-Bubble Contrast Agents (Definity® [Perflutren Lipid Microsphere] Injectable Suspension and Optison® [Perflutren Protein-Type A Microspheres] for Injection): Risk of Cardiopulmonary Reactions and Changes to Package Labeling | 7/18/2008 | National PBM Alert |
| Nationwide Recall of Sodium Polystyrene Sulfonate Suspension, USP (15g/60ml) (NDC 0054-0165-51; Lot 856396A Expiration April 2010, and Lot 856693A ExpirationMay 2010) | 7/17/2008 | National PBM Alert |
| Nationwide Recall of Sodium Polystyrene Sulfonate Suspension, USP (15g/60ml) (NDC 0054-0165-51; Lot 856396A Expiration April 2010, and Lot 856693A ExpirationMay 2010) | 7/17/2008 | Patient Letter |
| Fluoroquinolone Use and the Potential for Tendinitis and Tendon Rupture | 7/10/2008 | National PBM Bulletin |
| CellCept® (mycophenolate mofetil) and Cases of Progressive Multifocal Leukoencephalopathy (PML) | 7/1/2008 | National PBM Bulletin |
| Varenicline (marketed as Chantix) and Recent Safety Issues | 6/20/2008 | Patient Letter (VA Secretary) |
| Antipsychotic Use and Increase Risk of Death in Patients with Dementia-Related Psychosis | 6/16/2008 | FDA Information for Healthcare Professionals |
| Becaplermin (Regranex) Safety Information and Labeling Changes | 6/11/2008 | National PBM Bulletin |
| Tumor Necrosis Factor (TNF) Antagonists and the Development of Lymphomas and Other Cancers in Children and Young Adults (< 18 years) | 6/4/2008 | FDA Early Communication |
| Varenicline (marketed as Chantix) and Recent Safety Issues | 5/30/2008 | National PBM Bulletin Addendum |
| Varenicline (marketed as Chantix) and Recent Safety Issues | 5/30/2008 | VA Patient Letter |
| Aprotinin (Trasylol®) and Increased Risk of Death and Other Serious Adverse Events – Temporary Suspension in Marketing | 5/16/2008 | National PBM Bulletin |
| Use of Abacavir or Didanosine and Higher Risk of Heart Attack | 4/4/2008 | National HIV/AIDS Program Commentary |
| Heparin Manufacturer Recalls | 4/2/2008 | B. Braun Internal Distribution Letter |
| Heparin Manufacturer Recalls | 3/28/2008 | FDA Firm Press Release – Covidien Voluntary recall of Heparin Pre-Filled Syringes |
| Use of Abacavir or Didanosine and Higher Risk of Heart Attack | 3/27/2008 | FDA Early Communication |
| Heparin Manufacturer Recalls | 3/27/2008 | Advanced Medical Internal Distribution Letter |
| Heparin Manufacturer Recalls | 3/21/2008 | Advanced Medical Manufacturer Letter |
| Heparin Manufacturer Recalls | 3/25/2008 | Advanced Medical Important Notice |
| Heparin Manufacturer Recalls | 3/21/2008 | FDA Firm Press Release for B.Braun Medical, Inc. |
| Heparin Manufacturer Recalls | 3/20/2008 | B.Braun Urgent Drug Recall |
| Update: Baxter Heparin Sodium Recall – Alternatives to Heparin Sodium | 3/19/2008 | Update |
| Etanercept and Tuberculosis and Infections | 3/14/2008 | Dear Healthcare Professional Letter (Amgen) |
| EPOGEN®/PROCRIT® and Aranesp® and Additional Trials Showing Increased Mortality and/or Tumor Progression | 3/7/2008 | Dear Healthcare Professional Letter (Amgen) |
| Update: Baxter Heparin Sodium Recall | 3/3/2008 | Update B. Braun – April 2008 |
| Calcium Supplements and Cardiovascular Disease in Older Women | 3/1/2008 | Review of a recent BMJ Article |
| Baxter - Allergic Reactions to Heparin Sodium | 2/19/2008 | National PBM Bulletin |
| Antiepileptic Drugs and Suicidality | 2/11/2008 | National PBM Bulletin |
| Temsirolimus (Torisel®) Final Dose Concentration | 2/7/2008 | National PBM Bulletin Addendum |
| Temsirolimus (Torisel®) Final Dose Concentration | 1/22/2008 | National PBM Bulletin |
| Haloperidol and Cyanocobalamin 1ML Vials – Look-Alike Safety Alert | 12/20/2007 | National PBM Bulletin |
| IV Haloperidol and Torsades de Pointe | 11/28/2007 | Updated Labeling |
| Myfortic® (mycophenolic acid) and Increased Risks of Pregnancy Loss and Congenital Malformations / Change from Pregnancy Category C to Pregnancy Category D | 11/27/2007 | Dear Healthcare Professional Letter (Novartis) |
| Varenicline (marketed as Chantix) and Suicidal Thoughts and Aggressive or Erratic Behavior | 11/20/2007 | FDA Early Communication |
| Varenicline (marketed as Chantix) and Suicidal Thoughts and Aggressive or Erratic Behavior | 11/20/2007 | FDA Patient Information Sheet |
| Varenicline (marketed as Chantix) and Suicidal Thoughts and Aggressive or Erratic Behavior | 11/20/2007 | PBM Update: Varenicline Safety |
| Rosiglitazone and Increased Risk of Myocardial Ischemia | 11/19/2007 | FDA Information for Healthcare Professionals |
| Erythropoiesis Stimulating Agents Safety Alert | 11/15/2007 | National PBM Bulletin Addendum |
| Sildenafil (marketed as Viagra and Revatio) Vardenafil (marketed as Levitra) Tadalafil (marketed as Cialis) and Hearing Loss | 11/14/2007 | FDA Information for Healthcare Professionals |
| Cefipime (marketed as Maxipime) and Increased Mortality | 11/14/2007 | FDA Early Communication |
| Aprotinin (Trasylol®) and Increased Risk of Death and Other Serious Adverse Events – Temporary Suspension in Marketing | 11/6/2007 | National PBM Bulletin |
| Codeine Use in Breast-Feeding Women | 10/9/2007 | National PBM Bulletin |
| Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 9/28/2007 | National PBM Bulletin |
| IV Haloperidol and Torsades de Pointe | 9/17/2007 | FDA MedWatch Summary |
| Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 9/11/2007 | FDA Alert |
| Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 9/11/2007 | Information for Healthcare Professionals (FDA) |
| Viracept (nelfinavir mesylate) and presence of ethyl methanesulfonate (EMS), a process-related impurity | 9/10/2007 | FDA Drug Safety Information |
| Entecavir (Baraclude® ) and potential for the development of HIV (human immunodeficiency virus) resistance in HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) | 8/16/2007 | Dear Healthcare Professional Letter (Bristol-Myers Squibb) |
| Rosiglitazone and Risk of Heart Failure | 8/14/2007 | FDA Information for Healthcare Professionals |
| Pioglitazone and Risk of Heart Failure | 8/14/2007 | FDA Information for Healthcare Professionals |
| Omeprazole (Prilosec®) and Esomeprazole (Nexium®) and Cardiovascular Events | 8/9/2007 | Early Communication about an Ongoing Safety Review |
| Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 8/1/2007 | Dear Healthcare Professional Letter (Roche) |
| Omalizumab (Xolair®) and Anaphylactic Reactions | 7/10/2007 | National PBM Bulletin |
| Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products | 7/5/2007 | FDA Alert |
| Trimetrexate Glucuronate (Neutrexin®) and Drug Discontinuation | 3/16/2007 | Dear Healthcare Professional Letter |
| Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products | 6/1/2007 | Dear Healthcare Professional Letter |
| Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance) and Risk for Nephrogenic Systemic Fibrosis | 5/23/2007 | FDA Alert |
| Rosiglitazone (Avandia®) and Cardiovascular Events | 5/22/2007 | Information for Healthcare Professionals |
| Rosiglitazone (Avandia®) and Cardiovascular Events | 5/21/2007 | FDA Alert |
| Rosiglitazone (Avandia®) and Cardiovascular Events | 5/21/2007 | FDA News |
| Pergolide (Permax®) and Heart Valve Damage | 5/14/2007 | National PBM Bulletin |
| Antidepressant Medications and New Warnings About Suicidal Thinking, Behavior in Young Adults | 5/2/2007 | FDA Press Release |
| Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 5/1/2007 | Prescribing Information (Roche) |
| Zolpidem (Ambien®) High Dose Use and Dose-Related Adverse Events | 5/1/2007 | Review of Various Trials Using Zolpidem at Higher Doses |
| Look-Alike Sound-Alike Confusion Potential with Humapen Memoir® and Humira® Pen | 4/5/2007 | Humira Pen and HumaPen; ISMP Newsletter |
| Tegaserod and Discontinued Marketing for Safety Reasons | 4/3/2007 | National PBM Bulletin |
| Methadone (Dolophine®) and Serious Side Effects | 4/1/2007 | Methadone Related Deaths; PBM Ez Minutes April-June 2007 |
| Pergolide (Permax®) and Heart Valve Damage | 3/29/2007 | FDA Public Health Advisory |
| Lamivudine and Zidovudine (Combivir®) Tablets and Counterfeit Labeling | 3/28/2007 | Dear Pharmacy Professional Letter |
| Linezolid (Zyvox®) and Increased Mortality | 3/16/2007 | FDA Alert |
| Linezolid (Zyvox®) and Increased Mortality | 3/16/2007 | Healthcare Professional Sheet |
| Telithromycin (Ketek®) and Safety Issues | 3/1/2007 | Dear Healthcare Professional Letter |
| Omalizumab (Xolair®) and Anaphylactic Reactions | 2/21/2007 | FDA Alert |
| Omalizumab (Xolair®) and Anaphylactic Reactions | 2/21/2007 | FDA News |
| Omalizumab (Xolair®) and Anaphylactic Reactions | 2/21/2007 | Healthcare Professional Sheet |
| Telithromycin (Ketek®) and Serious Liver Toxicity | 2/12/2007 | FDA News – Label and Indication Changes |
| Telithromycin (Ketek®) and Serious Liver Toxicity | 2/12/2007 | Questions and Answers on Telithromycin |
| Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects | 2/8/2007 | National PBM Bulletin |
| IV Promethazine (Phenergan®) and Tissue Injury | 2/1/2007 | A Guidance on IV Promethazine Use and Safety Issues |
| Erythropoiesis Stimulating Agents Safety Alert | 1/9/2007 | National PBM Bulletin |
| Erythropoiesis Stimulating Agents Safety Alert | 1/9/2007 | Safety Concerns of Erythropoiesis Stimulating Agents |
| Look-Alike Sound-Alike Confusion Potential with Humapen Memoir® and Humira® Pen | 1/1/2007 | Two Pens Different Uses; PBM Ez-Minutes January-March 2007 |
| Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects | 1/1/2007 | Quinine Not for Leg Cramps Anymore; PBM Ez-Minutes January-March 2007 |
| Rituximab (Rituxan®) and Progressive Multifocal Leukoencephalopathy | 12/18/2006 | FDA Alert |
| Rituximab (Rituxan®) and Progressive Multifocal Leukoencephalopathy | 12/18/2006 | FDA Information for Healthcare Professionals |
| Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects | 12/11/2006 | FDA News |
| Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects | 12/11/2006 | FDA Questions and Answers on Unapproved Quinine Products |
| Methadone (Dolophine®) and Serious Side Effects | 11/30/2006 | National PBM Bulletin |
| Methadone (Dolophine®) and Serious Side Effects | 11/30/2006 | VAMedSAFE Bulletin |
| Methadone (Dolophine®) and Serious Side Effects | 11/27/2006 | FDA Alert |
| Methadone (Dolophine®) and Serious Side Effects | 11/27/2006 | Healthcare Provider Information |
| Oseltamivir Phosphate (Tamiflu®) and Precaution for Neuropsychiatric Events | 11/13/2006 | Dear Healthcare Professional Letter |
| Fluarix® and Twinrix® Look-Alike Confusion Potential | 11/1/2006 | National PBM Bulletin |
| Bevacizumab | 10/1/2006 | National PBM Bulletin |
| Look-Alike Sound-Alike Vaccine Mix-ups: Adacel (Tdap) and Daptacel (DTaP) | 8/24/2006 | ISMP Newsletter |
| IV Promethazine (Phenergan®) and Tissue Injury | 8/10/2006 | ISMP Newsletter |
| Telithromycin (Ketek®) and Serious Liver Toxicity | 7/5/2006 | Questions and Answers on Telithromycin |
| Telithromycin (Ketek®) and Serious Liver Toxicity | 6/29/2006 | FDA News for New Product Labeling Regarding Safety Issues |
| Benzocaine | 2/28/2006 | A Guidance on the Use of topical Anesthetics for Naso/Oropharyngeal and Laryngotracheal Procedures |
| Benzocaine | 2/10/2006 | FDA Public Health Advisory |
| Benzocaine | 2/8/2006 | NCPS Patient Safety Alert |
| Telithromycin (Ketek®) and Serious Liver Toxicity | 1/20/2006 | FDA Public Health Advisory |
| Telithromycin (Ketek®) and Serious Liver Toxicity | 1/20/2006 | Questions and Answers on Telithromycin |
| Benzocaine | 10/1/2005 | VAMedSAFE Patient Safety Issues – Benzocaine (Hurricaine Spray); PBM Ez-Minutes October-December 2005 |
| Phosphodiesterase 5 Inhibitors and Loss of Vision | 8/5/2005 | National PBM Bulletin |
| Clinical Guidance on Replacement Product Recommendations for Avandamet
and Paxil CR in the VA | 3/29/2005 | National PBM Bulletin |
| Vitamin E | 1/13/2005 | National PBM Bulletin |
| Ethyl Chloride Safety Awareness | 1/1/2005 | Ethyl Chloride Ignites; PBM Ez-Minutes January-March 2005 |
| Fentanyl Transdermal Patch | 12/22/2004 | National PBM Bulletin |
| HIV Agents New on Formulary | 12/21/2004 | National PBM Bulletin |
| Vitamin E | 12/1/2004 | VAMedSAFE Bulletin |
| Vitamin E | 12/1/2004 | Background: High Dose Vitamin E (> 400IU/Day) |
| Statins | 9/1/2004 | Statin-Fibrate Report – Focus on Safety |
| Rofecoxib | 7/21/2004 | National PBM Bulletin |
| Statins | 12/1/2001 | Recommendations for the Use of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors (statins) in Veteran Patients Receiving Medications with the Potential for Drug-Drug Interactions |
| Oxycontin – Diversion and Abuse | 12/1/2001 | VA Office of Inspector General Pharmaceutical Bulletin |
